ReviewEuropean respiratory review : an official journal of the European Respiratory Society2016
Risk assessment in pulmonary arterial hypertension.
Review in European respiratory review : an official journal of the European Respiratory Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05618093 (Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Pulmonary arterial hypertension in the elderly: Clinical perspectives.Cardiology journal · 2020Pooled it
- Predictive Value of the Pulmonary Artery Pulsatility Index in Pulmonary Arterial Hypertension: REVEAL Analysis.Cardiology research · 2026Article
- Expert consensus on patient engagement strategies for improving patient activation and shared decision making in pulmonary arterial hypertension.Journal of the American Association of Nurse Practitioners · 2026Article
- Low DLCO Can Provide Insights into Treatment Response in PAH Patients Irrespective of the Reason for Its Decrease.Life (Basel, Switzerland) · 2025Article
- Performance of Risk-Stratification Scores for Patients With Pulmonary Arterial Hypertension in a Multi-Ethnic Asian Population.Pulmonary circulation · 2025Article
- Article
- Characteristics and outcomes of gemcitabine-associated pulmonary hypertension.ERJ open research · 2024Article
- Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension.Pulmonary circulation · 2023Review
- Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives.Journal of clinical medicine · 2023Review
- Shikonin improves pulmonary vascular remodeling in monocrotaline‑induced pulmonary arterial hypertension via regulation of PKM2.Molecular medicine reports · 2023Article
- The SOCE Machinery: An Unbalanced Knowledge between Left and Right Ventricular Pathophysiology.Cells · 2022Review
- Telehealth: A winning weapon to face the COVID-19 outbreak for patients with pulmonary arterial hypertension.Vascular pharmacology · 2022Article
- Article
- Prediction of maximal oxygen uptake from 6-min walk test in pulmonary hypertension.ERJ open research · 2022Article
- Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.Journal of clinical medicine · 2021Article
- Does pulmonary artery pulsatility index predict mortality in pulmonary arterial hypertension?ESC heart failure · 2021Article
- Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension.ESC heart failure · 2021Article
- The Value of Heart Rhythm Complexity in Identifying High-Risk Pulmonary Hypertension Patients.Entropy (Basel, Switzerland) · 2021Article
- Article
- Management of Pulmonary Arterial Hypertension Patients with World Health Organization Functional Class II.Acta Cardiologica Sinica · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regular patient assessment is essential for the management of chronic diseases, such as pulmonary arterial hypertension (PAH). Comprehensive patient assessment and risk stratification in PAH are important to guide treatment decisions and to monitor disease progression as well as patients' response to treatment. Approaches for assessing risk in PAH patients include the use of risk variables, as recommended in the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) pulmonary hypertension (PH) guidelines, and the application of risk equations and scores, such as the French registry risk equation and the REVEAL registry risk score. Risk stratification and risk scores are both useful predictors of survival on a population basis, and provide an estimate for individual patients' risk. The 2015 ESC/ERS PH guidelines recommend regular assessment of multiple variables at an expert centre. The respective merits and limitations of different risk assessment methods in PAH are discussed in this article, as well as some considerations that can be taken into account in the future development of risk assessment tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.